ArticleCancer medicine2013
EGFR, KRAS, BRAF, and HER-2 molecular status in brain metastases from 77 NSCLC patients.
Article in Cancer medicine, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 36 citations in OpenAlex.
- Randomized trial of erlotinib plus whole-brain radiotherapy for NSCLC patients with multiple brain metastases.Journal of the National Cancer Institute · 2014Trial
- Liquid biopsy-based genomic risk score to predict neurologic death in non-small cell lung cancer patients.Journal of neuro-oncology · 2026Article
- Prevention of Brain Metastases: A New Frontier.Cancers · 2024Review
- Neuroanatomical location of lung cancer brain metastases in 234 patients with a focus on cancer subtyping and biomarkers.PloS one · 2024Article
- Advancing non-small cell lung cancer treatment: the power of combination immunotherapies.Frontiers in immunology · 2024Review
- Single-center study on clinicopathological and typical molecular pathologic features of metastatic brain tumor.Journal of pathology and translational medicine · 2023Article
- Evaluating the intracranial activity of adagrasib.Translational lung cancer research · 2023Article
- Brain metastases and lung cancer: molecular biology, natural history, prediction of response and efficacy of immunotherapy.Frontiers in immunology · 2023Review
- The treatment of advanced non-small cell lung cancer harboring KRAS mutation: a new class of drugs for an old target-a narrative review.Translational lung cancer research · 2022Review
- Epidermal growth factor receptor mutations and brain metastases in non-small cell lung cancer.Frontiers in oncology · 2022Review
- Review
- Elevation of EIF4G1 promotes non-small cell lung cancer progression by activating mTOR signalling.Journal of cellular and molecular medicine · 2021Article
- The prevalence and prognostic value of KRAS co-mutation subtypes in Chinese advanced non-small cell lung cancer patients.Cancer medicine · 2020Article
- Lung Cancer in Young Patients: Higher Rate of Driver Mutations and Brain Involvement, but Better Survival.Journal of global oncology · 2019Article
- Intratumor heterogeneity and tissue distribution of KRAS mutation in non-small cell lung cancer: implications for detection of mutated KRAS oncogene in exhaled breath condensate.Journal of cancer research and clinical oncology · 2019Article
- Risk factors for brain metastases in patients with non-small-cell lung cancer.Cancer medicine · 2018Review
- Screening for gene mutations in central nervous system metastases of non-small-cell lung cancer.Brain pathology (Zurich, Switzerland) · 2018Article
- Lung cancer-associated brain metastasis: Molecular mechanisms and therapeutic options.Cellular oncology (Dordrecht, Netherlands) · 2017Review
- Prevalence of NRAS, PTEN and AKT1 gene mutations in the central nervous system metastases of non-small cell lung cancer.Brain tumor pathology · 2017Article
- Frequency of BRAF V600E mutations in 969 central nervous system neoplasms.Diagnostic pathology · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The aim of this study was to determine the frequency of EGFR, KRAS, BRAF, and HER-2 mutations in brain metastases from non-small cell lung carcinomas (BM-NSCLC). A total of 77 samples of BM-NSCLC were included and 19 samples of BM from breast, kidney, and colorectal tumors were also studied as controls. These samples were collected from patients followed between 2008 and 2011 at Poitiers and Nice University Hospitals in France. The frequencies of EGFR, KRAS, BRAF, and HER-2 mutations in BM-NSCLC were 2.6, 38.5, 0, and 0% respectively. The incidence of KRAS mutation was significantly higher in female and younger patients (P < 0.05). No mutations of the four genes were found in BM from breast or kidney. However, among six BM from colorectal tumors, we identified KRAS mutations in three cases and BRAF mutations in two other cases. This study is the largest analysis on genetic alterations in BM-NSCLC performed to date. Our results suggest a low frequency of EGFR mutations in BM-NSCLC whereas KRAS mutations are as frequent in BM-NSCLC as in primitive NSCLC. These results raise the question of the variability of the brain metastatic potential of NSCLC cells in relation to the mutation pattern.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.